USDA approves Merck Animal Health’s NOBIVAC NXT canine flu H3N2

Innovative technology represents a breakthrough scientific achievement for highly contagious respiratory disease

Merck completes € 180 million investment to expand Schnelldorf Distribution Center

Merck has opened its newly expanded Life Science distribution center in Schnelldorf, Germany

Moderna & Merck announce 3-year data for mRNA-4157 in combination with Keytruda

The companies have initiated Phase 3 studies in patients with high-risk melanoma and non-small cell lung cancer

Merck's oncology pipeline of DDRi and ADC poised to advance cancer treatment

Merck shared updates on the company’s oncology pipeline and focused R&D approach

Merck Specialities’ unique initiative to raise bladder cancer awareness

Merck inks MoU with KAIST to advance scientific collaboration

Partnership to facilitate collaborative research in academia and industry to further progress in life sciences

FDA grants priority review to Merck’s application for Keytruda plus chemotherapy for metastatic malignant pleural mesothelioma

Acceptance based on results demonstrated a statistically significant improvement in overall survival versus chemotherapy alone in these patients

Merck KGaA to set up € 300 million Bioprocessing Production Center in South Korea

The new facility will accelerate the biotech and pharmaceutical industry's development by manufacturing vaccines, cell and gene therapies, and protein-based therapies

Merck to acquire EyeBio for US$ 1.3 billion upfront payment

Acquisition includes Restoret, a novel late-phase candidate for diabetic macular edema and neovascular age-related macular degeneration

Merck to showcase advances in the science of cancer with new data presented at ASCO 2024

Phase I data for tuvusertib, lead asset from the company’s unique portfolio of DDR inhibitors